{"id":"W3137057543","doi":"10.1016/j.jtho.2021.10.014","title":"Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Eli Lilly Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Teijin Pharma; Daiichi-Sankyo; Taiho Pharmaceutical; Chugai Pharmaceutical; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Boehringer Ingelheim; Amgen; Pfizer; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Epidermal growth factor receptor; Cancer; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001645098,0.000161949,0.0006737016,0.0001020141,0.00009676269,0.00003898476,0.00005758613,0.0001402084,0.0002688737],"category_scores_gemma":[0.0003628066,0.000106923,0.0001650709,0.000139444,0.00006766553,0.000185377,0.00001519569,0.0002220252,0.000003576818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002494402,"about_ca_system_score_gemma":0.001075711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009072867,"about_ca_topic_score_gemma":0.00004790326,"domain_scores_codex":[0.9988251,0.0001561399,0.0004627419,0.00019552,0.0001734864,0.0001870537],"domain_scores_gemma":[0.9979735,0.0004960818,0.0003346724,0.0001532671,0.0008753618,0.0001671409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02746843,0.002658057,0.07702761,0.00004168012,0.007326935,0.002377426,0.01064888,0.00001501761,0.1717586,0.00007602292,0.008222668,0.6923787],"study_design_scores_gemma":[0.02905385,0.01356674,0.7332557,0.0003996426,0.001882709,0.001999289,0.004020365,0.0001295599,0.1021708,0.001122298,0.1120229,0.0003761106],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9666819,0.003775315,0.0002437979,0.02814228,0.0004112335,0.0004277942,0.00005037881,0.00001438096,0.0002529378],"genre_scores_gemma":[0.9804686,0.001334298,0.009539153,0.006998218,0.0001888654,0.00002272488,0.00005934626,0.00003174883,0.001357022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6920026,"threshold_uncertainty_score":0.4360194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04007172802736948,"score_gpt":0.4578091412325619,"score_spread":0.4177374132051925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}